Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CCR4 | P51679 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566636 | 1.00 | GAA (0.35) | GAALMNAALDH1A1RXFP1L3MBTL1 | |
| SCHEMBL24309340 | 0.81 | USP1 (0.31) | GAALMNAALDH1A1CCR4TSHR | |
| SCHEMBL29567059 | 0.81 | USP1 (0.31) | GAALMNAALDH1A1CCR4TSHR | |
| SCHEMBL24310735 | 0.80 | PIK3CD (0.39) | GAAALDH1A1POLBTSHRKMT2A | |
| SCHEMBL24310518 | 0.73 | TSHR (0.40) | GAALMNAALDH1A1TSHRKMT2A | |
| SCHEMBL26807044 | 0.71 | LMNA (0.56) | LMNAALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL24309239 | 0.69 | CCNT1 (0.40) | GAAALDH1A1POLBTSHRKMT2A | |
| SCHEMBL26806587 | 0.69 | TSHR (0.40) | GAAALDH1A1POLBHTTTSHR | |
| SCHEMBL29566540 | 0.68 | BRD4 (0.37) | GAALMNACCR4POLBHTT | |
| SCHEMBL24309952 | 0.68 | MAP4K1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | GAA 904/4885LMNA 4052/4885ALDH1A1 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.